Cellectar Biosciences, Inc. announced financial results for the year ended December 31, 2025, reporting a net loss of $21.8 million or $8.35 per basic and diluted share, compared to $44.6 million or $36.52 per basic share in 2024. Cash and cash equivalents stood at $13.2 million as of December 31, 2025, adequate to fund basic operations into Q3 2026, alongside pipeline updates including planned CMA submission for iopofosine I 131 in Q3 2026.
Key takeaways
Net loss $21.8 million or $8.35 per basic/diluted share for year ended Dec 31, 2025 vs $44.6 million or $36.52 per basic share in 2024
Cash and cash equivalents $13.2 million as of Dec 31, 2025 vs $23.3 million as of Dec 31, 2024, funding operations into Q3 2026
R&D expenses $11.5 million in 2025 vs $26.1 million in 2024
G&A expenses $11.5 million in 2025 vs $25.6 million in 2024
On track for Conditional Marketing Authorization submission for iopofosine I 131 to EMA in Q3 2026 for Waldenström Macroglobulinemia
Initiated Phase 1b study of CLR 125 in triple negative breast cancer with early data expected mid-2026